Seliciclib
What is Seliciclib?
Seliciclib (roscovitine or CYC202) is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase or state within the cell cycle of treated cells. Seliciclib is being developed by Cyclacel.
Seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), Cushing's Disease, leukemia, HIV infection, herpes simplex infection, cystic fibrosis and the mechanisms of chronic inflammation disorders.
Questions and answers on "Seliciclib"
Recent questions on Seliciclib
Related Disease & Conditions
Related Drugs/Medications
Related Treatment/Therapy